<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT05027711</url>
  </required_header>
  <id_info>
    <org_study_id>RADONK-MAESTRO-2020</org_study_id>
    <nct_id>NCT05027711</nct_id>
  </id_info>
  <brief_title>Magnetic Resonance-guided Adaptive Stereotactic Body Radiotherapy for Hepatic Metastases</brief_title>
  <acronym>MAESTRO</acronym>
  <official_title>Magnetic Resonance-guided Adaptive Stereotactic Body Radiotherapy for Hepatic Metastases - MAESTRO -</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University Hospital Heidelberg</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>University Hospital Heidelberg</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      Stereotactic body radiotherapy (SBRT) is an established local treatment method for patients&#xD;
      with hepatic oligometastases. Liver metastases often occur in close proximity to&#xD;
      radiosensitive organs at risk (OARs). This limits the possibility to apply sufficiently high&#xD;
      doses needed for optimal local control. MR-guided radiotherapy (MRgRT) is expected to hold&#xD;
      potential to improve hepatic SBRT by offering superior soft-tissue contrast for enhanced&#xD;
      target identification as well as the benefit of daily real-time adaptive treatment. The&#xD;
      MAESTRO trial therefore aims to assess the potential advantages of adaptive, gated MR-guided&#xD;
      SBRT (MRgSBRT) compared to conventional SBRT at a standard linac using an ITV (internal&#xD;
      target volume) approach (ITV-SBRT).&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Hepatic SBRT is a well-established local treatment method for technically or medically&#xD;
      inoperable hepatic metastases. However, clinicians are often restricted in the utilization of&#xD;
      hepatic SBRT due to dose limitations of the uninvolved liver and nearby OARs (e.g. small&#xD;
      bowel, stomach, kidney). MR-guided radiotherapy with its superior soft-tissue contrast is&#xD;
      believed to facilitate the precise detection of tumor position and interfractional changes in&#xD;
      patient anatomy. Respiratory gating at the MR-Linac enables real-time visualization of the&#xD;
      tumor as well as synchronization of beam delivery to the patient's breathing . Therefore,&#xD;
      safety margins and thus the irradiated volume can possibly be decreased with MRgSBRT in&#xD;
      comparison to ITV-based SBRT, reducing the risk of treatment-associated toxicity. Hepatic&#xD;
      MRgSBRT of smaller target volumes might further offer the possibility of dose escalation for&#xD;
      increasing local control. To our knowledge, only two retrospective analyses including 26 and&#xD;
      29 patients as well as one case report about hepatic MR-guided SBRT using a MR-Linac can be&#xD;
      found in literature. As MR-guided adaptive SBRT is very staff intense and time consuming&#xD;
      compared to standard ITV-based SBRT, prospective studies are needed to demonstrate the&#xD;
      expected benefits of MR-guided adaptive SBRT. This trial will be conducted as a prospective,&#xD;
      randomized, three-armed phase II study in 82 patients with hepatic metastases (solid&#xD;
      malignant tumor, 1-3 hepatic metastases confirmed by magnetic resonance imaging (MRI),&#xD;
      maximum diameter of each metastasis ≤ 5 cm (in case of 3 metastases: sum of diameters ≤&#xD;
      12cm), age ≥ 18 years, Karnofsky Performance Score ≥ 60%). If a biologically effective dose&#xD;
      (BED) ≥ 100 Gy is feasible based on ITV-based planning, patients will be randomized to either&#xD;
      MRgSBRT (Arm A) or ITV-based SBRT (Arm B). If a lesion cannot be treated with a BED ≥ 100 Gy,&#xD;
      the patient will be treated in Arm C with MRgSBRT at the highest possible dose.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">August 12, 2021</start_date>
  <completion_date type="Anticipated">January 31, 2026</completion_date>
  <primary_completion_date type="Anticipated">January 31, 2024</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Treatment related Toxicity</measure>
    <time_frame>within the first year after radiation treatment</time_frame>
    <description>occurrence of treatment-related gastrointestinal or hepatobiliary CTCAE V5.0 toxicity of grade III or higher</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Treatment related Toxicity</measure>
    <time_frame>within 24 months after radiation treatment</time_frame>
    <description>assesment of toxicity according to CTCAE V5.0 in all three treatment groups</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Treatment related Quality of life</measure>
    <time_frame>within 24 months after radiation treatment</time_frame>
    <description>Changes in quality of life according to EORTC QLQ C-30</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Treatment related Quality of life</measure>
    <time_frame>within 24 months after radiation treatment</time_frame>
    <description>Changes in quality of life according to EORTC QLQ LMC-21</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>local Tumor Control</measure>
    <time_frame>within 24 months after radiation treatment</time_frame>
    <description>Change of local Tumor size at one specific site</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>locoregional control</measure>
    <time_frame>within 24 months after radiation treatment</time_frame>
    <description>Change of local Tumor size within a defined local region</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>distant tumor control</measure>
    <time_frame>within 24 months after radiation treatment</time_frame>
    <description>apparence of distant Tumor leasions</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>progression-free survival (PFS)</measure>
    <time_frame>24 months after radiation treatment</time_frame>
    <description>time of suvival without Tumor progression</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>overall survival (OS)</measure>
    <time_frame>24 months after radiation treatment</time_frame>
    <description>time of Survival of studypopulation</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Changes in applied biological effective doses (BED) to the target Volumen (Tumor)</measure>
    <time_frame>through study completion, an average of 1 year</time_frame>
    <description>BED increase and OAR doses with MRgSBRT compared to initial ITV-based planning in arms A and C</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Evaluation of potential prognostic biomarkers</measure>
    <time_frame>within 24 months after radiation treatment</time_frame>
    <description>Changes in blood Levels of blood Parameters compared to reference samples</description>
  </secondary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Anticipated">90</enrollment>
  <condition>Hepatic Metastasis</condition>
  <arm_group>
    <arm_group_label>A</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Magnetic Resonance-guided Stereotactic Body Radiotherapy (MRgSBRT), if a biologically effective dose (BED) of ≥ 100 Gy is achievable using an ITV</description>
  </arm_group>
  <arm_group>
    <arm_group_label>B</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>ITV (Internal target volume)-based Stereotactic Body Radiotherapy (ITV-SBRT), if a biologically effective dose (BED) of ≥ 100 Gy is achievable using an ITV</description>
  </arm_group>
  <arm_group>
    <arm_group_label>C</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Magnetic Resonance-guided Stereotactic Body Radiotherapy (MRgSBRT). If a BED of ≥ 100 Gy cannot be achieved using an ITV concept (e.g. due to OAR constraints), patients will be treated in arm C using MRgSBRT with the highest achievable dose as deemed appropriate by the treating radiation oncologist</description>
  </arm_group>
  <intervention>
    <intervention_type>Radiation</intervention_type>
    <intervention_name>ITV (Internal target volume)-based Stereotactic Body Radiotherapy (ITV-SBRT)</intervention_name>
    <description>ITV (Internal target volume)-based Stereotactic Body Radiotherapy (ITV-SBRT)</description>
    <arm_group_label>B</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Radiation</intervention_type>
    <intervention_name>MRgSBRT (Magnetic Resonance-guided Stereotactic Body Radiotherapy)</intervention_name>
    <description>MRgSBRT (Magnetic Resonance-guided Stereotactic Body Radiotherapy)</description>
    <arm_group_label>A</arm_group_label>
    <arm_group_label>C</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  confirmed underlying solid malignant tumor (no germ cell tumor, leukemia, lymphoma)&#xD;
&#xD;
          -  1-3 hepatic metastases confirmed by pre-therapeutic MRI&#xD;
&#xD;
          -  indication for SBRT of 1-3 hepatic metastases&#xD;
&#xD;
          -  maximum diameter each hepatic metastasis ≤ 5 cm (in case of 3 metastases: sum of&#xD;
             diameters ≤ 12 cm)&#xD;
&#xD;
          -  age ≥ 18 years of age&#xD;
&#xD;
          -  Karnofsky Performance Score ≥ 60%&#xD;
&#xD;
          -  ability to lie still on the radiotherapy treatment couch for at least one hour&#xD;
&#xD;
          -  ability to hold one's breath for more than 25 seconds&#xD;
&#xD;
          -  for women with childbearing potential, adequate contraception&#xD;
&#xD;
          -  ability of subject to understand character and individual consequences of the clinical&#xD;
             trial&#xD;
&#xD;
          -  written informed consent (must be available before enrolment in the trial)&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  refusal of the patients to take part in the study&#xD;
&#xD;
          -  patients with primary liver cancer (eg. HCC, CCC)&#xD;
&#xD;
          -  patients after liver transplantation&#xD;
&#xD;
          -  impairment of liver function to an extent contraindicating radiotherapy (to the&#xD;
             discretion of the treating radiation oncologist)&#xD;
&#xD;
          -  active acute hepatic/biliary infection (e.g. hepatitis, cholangitis, cholecystitis)&#xD;
&#xD;
          -  previous radiotherapy of the hepatobiliary system, if previous and current target&#xD;
             volumes overlap MAESTRO Study Studienprotokoll Seite 25 von 54 Version 1.0 vom&#xD;
             17.12.2020&#xD;
&#xD;
          -  patients who have not yet recovered from acute toxicities of prior therapies&#xD;
&#xD;
          -  claustrophobia&#xD;
&#xD;
          -  pregnant or lactating women&#xD;
&#xD;
          -  contraindications against performing contrast-enhanced MRI scans (pacemakers, other&#xD;
             implants making MRI impossible, allergy to gadolinium (GD)-based contrast agent)&#xD;
&#xD;
          -  participation in another competing clinical study or observation period of competing&#xD;
             trials&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Juliane Hörner-Rieber, PD</last_name>
    <phone>+496221 56</phone>
    <phone_ext>2802</phone_ext>
    <email>juliane.hörner-rieber@med.uni-heidelberg.de</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Philipp Hoegen, MD</last_name>
    <phone>+496221 56</phone>
    <phone_ext>2802</phone_ext>
    <email>philipp.hoegen@med.uni-heidelberg.de</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>University Hospital of Heidelberg, Radiation Oncology</name>
      <address>
        <city>Heidelberg</city>
        <zip>69120</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <investigator>
      <last_name>Jürrgen Debus, MD PHD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>Germany</country>
  </location_countries>
  <verification_date>August 2021</verification_date>
  <study_first_submitted>August 3, 2021</study_first_submitted>
  <study_first_submitted_qc>August 25, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">August 30, 2021</study_first_posted>
  <last_update_submitted>August 25, 2021</last_update_submitted>
  <last_update_submitted_qc>August 25, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">August 30, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>University Hospital Heidelberg</investigator_affiliation>
    <investigator_full_name>Juergen Debus</investigator_full_name>
    <investigator_title>Department Head</investigator_title>
  </responsible_party>
  <keyword>Magentic Resonance-guided Adaptive Stereotactic Body Radiotherapy</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Neoplasm Metastasis</mesh_term>
    <mesh_term>Liver Neoplasms</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

